Latest Clinical News

Inherited pancreatic cancer risk mutation identified (08-15-2019)

Scientists have found a rare, inherited gene mutation that raises the risk of pancreatic cancer and other malignancies In the future, individuals with a strong family history of pancreatic cancer could be tested to determine if they carry the mutation. Scientists... Continue Reading

Vaccine for Acute Myeloid Leukemia? (08-14-2019)

A personalized cancer vaccine markedly improved outcomes for patients suffering from acute myeloid leukemia (AML), a potentially lethal blood cancer, in a clinical trial led by investigators at Beth Israel Deaconess Medical Center (BIDMC). The product... Continue Reading

FDA approves darolutamide for non-metastatic castration-resistant prostate cancer (08-1-2019)

FDA approves darolutamide for non-metastatic castration-resistant prostate cancer On July 30, 2019, the Food and Drug Administration approved darolutamide (NUBEQA, Bayer HealthCare Pharmaceuticals Inc.) for non-metastatic castration-resistant prostate... Continue Reading

Dana-Farber Opens New Clinical Trials for Patients with Endometrial Cancer (07-30-2019)

A recent dearth of clinical trials of treatments for endometrial cancer has segued into a research revival – including four new trials led by Dana-Farber investigators – spurred by advances in the scientific understanding of the disease. The trials... Continue Reading

FDA Approves Ruxience Biosimlar to Rituxan (07-25-2019)

The FDA approved rituximab-pvvr, a rituximab biosimilar, for use alone or in combination with chemotherapy for the treatment of adults with CD20-positive, B-cell non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL), as well as granulomatosis... Continue Reading

FDA grants breakthrough therapy designation to Keytruda-Lenvima combination for hepatocellular carcinoma (07-24-2019)

The FDA granted breakthrough therapy designation to pembrolizumab in combination with lenvatinib as first-line treatment for patients with advanced unresectable hepatocellular carcinoma who are not able to receive locoregional treatment. This is the third... Continue Reading

Bladder Cancer Advocacy Network Announces 2019 Bladder Cancer Research Innovation Awardee (07-17-2019)

(July 8, 2019, Bethesda, MD) Today, the Bladder Cancer Advocacy Network (BCAN) announced the recipient of its prestigious Bladder Cancer Research Innovation Award.  This year’s awardee is Philip Beachy, Ph.D., Professor of Urology and of Developmental... Continue Reading

Mouthwash reduces radiation-induced oral mucositis pain among patients with head and neck cancer (07-16-2019)

A mouthwash consisting of diphenhydramine, lidocaine and antacids significantly reduces oral mucositis pain when used in patients receiving radiation therapy for the treatment of head and neck cancer.   Researchers assigned 275 patients with head... Continue Reading

Using the Internet Wisely for Cancer Information (07-11-2019)

From Beth Israel Deaconess Medical Center The Internet is simultaneously the best and the worst of tools. This is especially true when related to a cancer patient’s search for support and information. Whereas people used to have to find medical libraries... Continue Reading

New Surgical Technique Shows Potential in Restoring Erectile Function After Radical Prostatectomy (07-9-2019)

Cancer Connect News: According to a report from Australian doctors published in the Journal of European Urology minimally invasive end to end nerve grafting can restore erectile function among men who previously underwent radical prostatectomy for prostate... Continue Reading

FDA Approves New Treatment for Multiple Myeloma (07-5-2019)

The FDA has granted accelerated approval to selinexor (Xpovio; Karyopharm Therapeutics) tablets in combination with the corticosteroid dexamethasone for the treatment of adults with relapsed or refractory multiple myeloma who received ≥4 previous therapies... Continue Reading

NIH study finds long-term increased risk of cancer death following common treatment for hyperthyroidism (07-2-2019)

Findings from a study of patients who received radioactive iodine (RAI) treatment for hyperthyroidism show an association between the dose of treatment and long-term risk of death from solid cancers, including breast cancer. The study, led by researchers... Continue Reading

Next Page »